曲妥珠单抗联合二线化疗治疗人表皮生长因子受体2阳性晚期乳腺癌患者的疗效  

Efficacy of trastuzumab combined with second-line chemotherapy in the treatment of patients with human epidermal growth factor receptor 2-positive advanced breast cancer

作　　者：孙起 仲立新[1] 张建东 SUN Qi;ZHONG Lixin;ZHANG Jiandong(Department of Oncology,Nanyang First People’s Hospital,Nanyang 473000,He’nan,China)

机构地区：[1]南阳市第一人民医院肿瘤内科,河南南阳473000

出　　处：《癌症进展》2025年第1期80-82,86,共4页Oncology Progress

摘　　要：目的探讨曲妥珠单抗联合二线化疗(环磷酰胺^(+)多西他赛)治疗人表皮生长因子受体2(HER2)阳性晚期乳腺癌患者的疗效。方法依据治疗方法的不同将150例HER2阳性晚期乳腺癌患者分为常规化疗组(69例,二线化疗)和联合曲妥珠单抗组(81例,二线化疗^(+)曲妥珠单抗),比较两组患者的治疗效果、T淋巴细胞亚群(CD3^(+)、CD4^(+)、CD8^(+)水平及CD4^(+)/CD8^(+))、生活质量[卡氏功能状态(KPS)评分]及随访3年的预后情况。结果联合曲妥珠单抗组患者总有效率高于常规化疗组,肿瘤复发率和死亡率均低于常规化疗组,差异有统计学意义(P﹤0.05)。治疗后,两组患者CD3^(+)、CD4^(+)水平及CD4^(+)/CD8^(+)均高于本组治疗前,CD8^(+)水平均低于本组治疗前,联合曲妥珠单抗组患者CD3^(+)、CD4^(+)水平均高于常规化疗组,CD8^(+)水平低于常规化疗组,差异均有统计学意义(P﹤0.05)。治疗后,两组患者KPS评分均高于本组治疗前,联合曲妥珠单抗组患者KPS评分高于常规化疗组,差异均有统计学意义(P﹤0.05)。结论曲妥珠单抗联合二线化疗治疗HER2阳性晚期乳腺癌患者疗效显著,可以改善患者的免疫功能和生活质量,并且患者预后较好。Objective To investigate the efficacy of trastuzumab combined with second-line chemotherapy(cyclophosphamide^(+)docetaxel)in the treatment of patients with human epidermal growth factor receptor 2(HER2)-positive advanced breast cancer.Method A total of 150 patients with HER2-positive advanced breast cancer were divided into conventional chemotherapy group(69 cases,second-line chemotherapy)and combined trastuzumab group(81 cases,secondline chemotherapy^(+)trastuzumab)according to different treatment methods.The therapeutic effect,T lymphocyte subsets(CD3^(+),CD4^(+),CD8^(+)levels and CD4^(+)/CD8^(+)),quality of life[Karnofsky performance status(KPS)score]and prognosis after 3 years of follow-up were compared between the two groups.Result The total effective rate of combined trastuzumab group was higher than that of conventional chemotherapy group,the tumor recurrence rate and mortality were lower than those of conventional chemotherapy group,and the differences were statistically significant(P<0.05).After treatment,the CD3^(+),CD4^(+)levels and CD4^(+)/CD8^(+)in two groups were higher than those before treatment,the CD8^(+)levels were lower than those before treatment,the CD3^(+)and CD4^(+)levels in combined trastuzumab group were higher than those in conventional chemotherapy group,the CD8^(+)level was lower than that in conventional chemotherapy group,and the differences were statistically significant(P<0.05).After treatment,the KPS scores in two groups were higher than those before treatment,the KPS score in combined trastuzumab group was higher than that in conventional chemotherapy group,and the differences were statistically significant(P<0.05).Conclusion Trastuzumab combined with second-line chemotherapy in the treatment of patients with HER2-positive advanced breast cancer is effective,which can improve the immune function and quality of life of patients,and the prognosis of patients is good.

关 键 词：曲妥珠单抗 二线化疗 人表皮生长因子受体2阳性 晚期乳腺癌 免疫功能 

分 类 号：R737.9[医药卫生—肿瘤]